Table 1

Baseline clinical characteristics of patients with T2D

Total
(N=703 745)
HRH (+)
(N=10 376)
HRH (−)
(N=693 369)
P value
Sex
Male434 569 (61.8)6274 (60.5)428 295 (61.8)0.007
Female269 176 (38.2)4102 (39.5)265 074 (38.2)
Age (years)70.4±12.371.8±11.570.4±12.2<0.001
20–64190 603 (27.1)2350 (22.6)188 253 (27.2)<0.001
65–74227 115 (32.3)3280 (31.6)223 835 (32.3)
≥75286 027 (40.6)4746 (45.7)281 281 (40.6)
BMI (kg/m2)24.1±4.322.7±4.324.1±4.3<0.001
≥25256 330 (36.4)2516 (24.2)253 814 (36,6)<0.001
<25447 415 (63.6)7860 (75.8)439 555 (63.4)
Hypoglycemic agents
Biguanides203 923 (29.0)2616 (25.2)201 307 (29.0)<0.001
DPP-4 inhibitors469 393 (66.7)7173 (69.1)462 220 (66.7)<0.001
Glinides81 736 (11.6)2039 (19.7)79 697 (11.5)<0.001
GLP-1 RA32 171 (4.6)831 (8.0)31 340 (4.5)<0.001
Insulin445 129 (63.3)8910 (85.9)436 219 (62.9)<0.001
SGLT2 inhibitors72 315 (10.3)726 (7.0)71 589 (10.3)<0.001
Sulfonylureas192 847 (27.4)4207 (40.5)188 640 (27.2)<0.001
Thiazolidines65 737 (9.3)1384 (13.3)64 353 (9.3)<0.001
α-GI158 055 (22.5)3738 (36.0)154 317 (22.3)<0.001
  • P values were calculated for differences between patients with and without hypoglycemic events.

  • BMI, body mass index; DPP-4, dipeptidyl peptidase-4; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HRH (+), patients with HRH events; HRH, hypoglycemia-related hospitalization; HRH (−), patients without HRH events; SGLT2, sodium-glucose co-transporter 2; T2D, type 2 diabetes; α-GI, alpha-glucosidase inhibitor.